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Mutations in the TP53 gene and microenvironmentally driven ac-
tivation of hypoxia-inducible factor-1 (HIF-1) typically occur in later
stages of tumorigenesis. An ongoing challenge is the identification
of molecular determinants of advanced cancer pathogenesis to
design alternative last-line therapeutic options. Here, we report
that p53 mutants influence the tumor microenvironment by coop-
erating with HIF-1 to promote cancer progression. We demon-
strate that in non-small cell lung cancer (NSCLC), p53 mutants
exert a gain-of-function (GOF) effect on HIF-1, thus regulating a
selective gene expression signature involved in protumorigenic
functions. Hypoxia-mediated activation of HIF-1 leads to the for-
mation of a p53 mutant/HIF-1 complex that physically binds the
SWI/SNF chromatin remodeling complex, promoting expression of
a selective subset of hypoxia-responsive genes. Depletion of
p53 mutants impairs the HIF-mediated up-regulation of extracel-
lular matrix (ECM) components, including type VIIa1 collagen and
laminin-γ2, thus affecting tumorigenic potential of NSCLC cells in
vitro and in mouse models in vivo. Analysis of surgically resected
human NSCLC revealed that expression of this ECM gene signature
was highly correlated with hypoxic tumors exclusively in patients
carrying p53 mutations and was associated with poor prognosis.
Our data reveal a GOF effect of p53 mutants in hypoxic tumors
and suggest synergistic activities of p53 and HIF-1. These findings
have important implications for cancer progression and might pro-
vide innovative last-line treatment options for advanced NSCLC.
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The TP53 gene (encoding the corresponding tumor suppressorprotein p53) is the most frequently mutated gene in all hu-
man cancers. These sequence alterations typically occur as mis-
sense mutations that abolish its tumor-suppressive activity and
lead to new oncogenic forms of p53 (1–5). The gain-of-function
(GOF) properties of mutant p53 have partially been explained by
its ability to physically interact with other transcriptional factors
and deregulate their transcriptional abilities (6–9). Indeed, al-
though canonical p53-mediated tumor suppression is strictly re-
lated to cell cycle arrest/apoptosis, accumulating evidence
highlights the involvement of mutant forms of p53 in processes
such as cancer metabolism, invasion/metastasis, and tumor mi-
croenvironment interactions (10, 11). However, understanding of
the impact of p53 mutants in different cellular, mutational, and
microenvironmental backgrounds is limited; despite this, it
would be critical to dissect the basis of the oncogenic phenotype
associated with mutant p53 and consequentially accelerate im-
provement of the management of oncological patients.
At the stage at which mutations in the TP53 gene occur, cancer
cells have frequently already been exposed to reduced oxygen
tension, which further promotes cancer progression through the
activation of hypoxia-inducible factor-1 (HIF-1) (12–16). Adap-
tation to the drop in oxygen level is indeed a key determinant for
progression of cancer toward the more advanced stages (12, 15).
The hypoxic microenvironment causes cancer cells to co-opt HIF-
dependent processes, which provides all of the required features
for cancer progression. HIF-1 coordinates the transcriptional
program required to acquire proangiogenic, invasive, and meta-
static properties, as well as metabolic adaptations and stemness,
which, collectively, constitute the lethal cancer phenotype (17).
Here, we report that GOF p53 mutants co-opt HIF-1 in hypoxic
non-small cell lung cancer (NSCLC) cells, thus inducing a selec-
tive HIF-1–dependent transcriptional response that promotes a
non–cell-autonomous protumorigenic signaling. A molecular com-
plex, including mutant p53 and HIF-1, directly promotes transcrip-
tional expression of extracellular matrix (ECM) components,
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including type VIIa1 collagen and laminin-γ2. Mechanistically,
recruitment of the SWI/SNF chromatin remodeling complex
determines selectivity of p53 mutants on this specific subset of
hypoxia-responsive genes. Modulation of the HIF-1/p53 mutant/
ECM axis influences the tumorigenic phenotype of NSCLC cells
in vitro and in mouse models in vivo. Clinical evidence indicates
that this ECM gene signature was highly correlated with hypoxic
tumors exclusively in patients carrying p53 mutations and was
associated with poor prognosis. Our findings suggest potential
alternative avenues for last-line treatment options for advanced
NSCLC harboring mutant p53.
Results
Hypoxia-Induced HIF-1 Binds p53 Mutant and Drives It on the
Chromatin. Mutations of the TP53 gene commonly occur with
intratumor hypoxia in later stages of tumor progression. Since the
life expectancy of patients with concurrent mutations at the TP53
locus and activation of hypoxic signaling is substantially lower than
predicted from the simple additive effect of these two prognostic
factors considered individually (Fig. 1A), we investigate here the
specific molecular pathways responsible for the synergism between
p53 mutants and hypoxia. Subcellular fractionation revealed that
hypoxia (1% O2) promoted enrichment of mutant p53 protein
content in the chromatin fraction of two different NSCLC cell
lines, NCI-H1155 (expressing p53 R273H) and NCI-H23
(expressing p53 R246I) (Fig. 1 B and C). No effect of hypoxia
on the p53 protein level was observed in whole-cell extracts (SI
Appendix, Fig. S1 A and B). This result indicates that hypoxia
does not alter the expression level of the p53 R273H and p53
R246I proteins. Because HIF-1 plays a predominant role in the
response to low oxygen concentrations, we examined whether
HIF-1 has a direct role in driving the binding of mutant p53 to
chromatin. Silencing HIF-1α dramatically abolished the accumula-
tion of p53 mutants in the chromatin-bound fractions of cells
treated with 1% O2 (Fig. 1D). Additionally, overexpression of
constitutively stable hydroxylated mutant HIF-1α [HA–HIF-1α PA:
P402A/P464A (18)] also increased the binding of mutant p53 to the
chromatin of cells grown in normoxia (Fig. 1E). Consistently, cobalt
chloride (CoCl2), which selectively stabilizes HIF-1α, recapitulated
the effect of hypoxia on the interaction of p53 mutants with chro-
matin (SI Appendix, Fig. S1 D and E), which was rescued by HIF-1α
depletion (SI Appendix, Fig. S2 A and C). As a comparison, we
tested whether wild-type (wt) p53 adopted similar behavior at low
oxygen concentrations. In the wt p53-expressing NSCLC cell line
A549, hypoxia did not alter the binding of wt p53 to chromatin (SI
Appendix, Fig. S2B), HIF-1α depletion consistently lacked an effect
on the wt p53 content in the chromatin-bound fraction (SI Ap-
pendix, Fig. S2C). In contrast to p53 mutants, wt p53 showed up-
regulated total protein levels in experiments of hypoxia and CoCl2
treatment (SI Appendix, Fig. S1C). In addition, wt p53 physically
bound HIF-1α through its DNA-binding domain (DBD) (SI Ap-
pendix, Fig. S2D), although HIF-1α appeared to be unstable within
the molecular complex with full-length p53. Indeed, consistent with
the previously reported negative regulation of wt p53 on HIF-1α
stability, depletion of wt p53 increased normoxic levels of HIF-1α
(SI Appendix, Fig. S2E). These last results were in agreement with
previous studies, reporting the hypoxia-dependent stabilization of
wt p53 (19, 20), a negative regulation of HIF-1α stability following
physical binding to wt p53 (21–23), and an involvement of this in-
terplay in p53-mediated hypoxic cell death (24–26).
HIF-1/p53 Mutant Complex Regulates Transcription of ECM Genes.We
next investigated the molecular basis underlying the binding of
mutant p53 to the chromatin under hypoxic stress. Coimmuno-
precipitation experiments revealed a physical interaction between
HIF-1α and the endogenous mutants p53 R273H and p53 R246I
in NSCLC cell lines cultured in the presence of CoCl2 (Fig. 1F and
SI Appendix, Fig. S3A). Similarly, a proximity ligation assay (PLA)
confirmed the presence of a nuclear molecular complex, including
mutant p53 and HIF-1α, under hypoxic conditions or upon HIF-1α
stabilization by CoCl2 treatment (SI Appendix, Fig. S3 B and C).
We next mapped the interaction between HIF-1α and p53 mutant.
We generated different constructs expressing Myc- or Flag-tagged
domains of HIF-1α or p53 R273H, respectively (SI Appendix,
Fig. S3 D and E). We then overexpressed these fragments in the
p53−/− NSCLC cell line NCI-H1299, together with full-length
HA-p53 R273H or Myc–HIF-1α, respectively. Coimmunoprecipi-
tation clearly revealed that the N-terminal fragment of HIF-1α
(HIF-1α1–330) and the DBD of p53 R273H were involved in the
physical interaction (Fig. 1 G and H). HIF-1α1–330 contains the
DBD [basic helix–loop–helix (bHLH) domain] and the Per–Arnt–Sim
(PAS)-A/B domain, which interact with HIF-1β, the oxygen-insensitive
subunit of HIF-1 (13). In addition, considering the presence of
the bHLH and PAS-A/B domains at the HIF-1β N terminus, we
explored whether HIF-1β interacts with p53 mutants to form a
preexisting complex that is potentially present under normoxic
conditions. However, a PLA showed no preexisting binding
between HIF-1β and mutant p53 under normoxia but did reveal
significant accumulation of the HIF-1β/mutant p53 complex
when HIF-1α was stabilized via CoCl2 treatment (SI Appendix, Fig.
S3F). This requirement of the HIF-1α subunit for the binding of
HIF-1β to mutant p53 indicated the existence of a complex con-
sisting of mutant p53 and fully transcriptionally active HIF-1 (the
HIF-1α/HIF-1β complex) under hypoxic conditions.
Missense mutations in p53 inactivate its DNA-binding ability,
but recent data suggest that interactions with active transcription
factors can mediate a p53 mutant-dependent transcriptional ef-
fect, which underlies its GOF properties (1, 9, 27). Therefore, we
explored whether interaction with HIF-1 and accumulation on the
chromatin under hypoxic stress could lead to the production of a
specific mutant p53/hypoxia-dependent gene expression signature.
We depleted p53 R273H from NCI-H1155 cells using siRNA,
followed by an 8-h incubation in 1% O2. Up-regulation of well-
established hypoxic genes (SI Appendix, Fig. S4A), as well as
accumulation of the hypoxia-dependent L-enantiomer of hydrox-
yglutarate (28, 29), confirmed successful activation of the hypoxia
response in our cellular model (SI Appendix, Fig. S6 B and C).
Then, we performed a global gene expression analysis (SI Ap-
pendix, Fig. S4 B–F). Comparison of the gene expression signa-
tures associated with p53 R273H deficiency under normoxic and
hypoxic conditions revealed a subgroup of ∼300 genes that are
regulated by mutant p53 predominantly during hypoxic stress (Fig.
2A). Mutant p53 deficiency did not alter the entire HIF-1–
dependent signature (SI Appendix, Fig. S5 A and B), indicating
the selective regulation of certain hypoxia-responsive genes by
mutant p53. In addition, there was no overlap with the wt p53-
dependent gene expression signature in hypoxic conditions (SI
Appendix, Fig. S2 F and G). To define the functional categories of
this subgroup of 300 p53 mutant/hypoxia-dependent genes, we
performed pathway analysis (Fig. 2B). The most highly repre-
sented pathway was “cellular movement,” which was clearly as-
sociated with the propensity of cancer cells to disseminate into
metastatic foci. This property was also represented in other cat-
egories, such as “cell morphology” and “cell interaction,” and this
observation suggests the ability of this mutant p53/hypoxia-
dependent gene expression signature to influence the interaction
of the tumor with the external microenvironment. Several genes
encoding components of the ECM, such as collagens and laminin
subunits, were included in a “cellular movement” group. The
ECM is dynamically modulated, particularly in a hypoxic micro-
environment, by multiple cell types, including cancer cells, thus
promoting cancer progression. Indeed, changes in the composi-
tion and overall content of the ECM influence both its biophysical
and biological properties, and these functions of the ECM, in turn,
significantly affect tumor and stromal cell properties, such as pro-
liferation and motility [reviewed by Gilkes et al. (17)]. Therefore, we
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Fig. 1. Hypoxia-driven HIF-1 promotes the binding of p53 mutants to genomic DNA. (A) Kaplan–Meier plot indicating the overall survival estimates for
patients with NSCLC presenting a mutation in the TP53 gene and activation of hypoxia (measured as a signature, including 10 different hypoxia-responsive
genes). Datasets: The Cancer Genome Atlas (TCGA) lung adenocarcinoma (LUAD) and METABRIC breast cancer. The P value is indicated in the panel. “Others”
indicates all of the samples not included in the hypoxia/mut-p53 groups (samples not presenting concurrent high signature and p53 mutant status). The table
displays the median survival (months) of the patients comprising the different subgroups. (B and C) Western blot analysis of subcellular fractions (nuclear-
soluble and chromatin-bound fractions) of NCI-H1155 and NCI-H23 cells treated with 1% oxygen for 4 h. Histograms show the ratio of Chr-bound/Nucl protein
contents calculated via densitometry of Western blots. Chr, chromatin-bound fraction; Nucl, soluble nuclear fraction; MW, molecular weight (molecular mass);
Nx, normoxia. (D) Western blot analysis of subcellular fractions of NCI-H1155 and NCI-H23 cells treated with 1% oxygen for 4 h following HIF-1α depletion
using siRNA. CTR, control. (E) Western blot analysis of nuclear-soluble and chromatin-bound fractions of NCI-H23 cells overexpressing the HA-tagged HIF-1α
PA mutant. The histogram shows the ratio of chromatin-bound/nuclear protein contents calculated via densitometry of Western blots. Error bars (in B, C, and
E) indicate the SD of three densitometry measurements. (F) Coimmunoprecipitation of endogenous HIF-1αwith p53 mutants (p53 R273H from NCI-H1155 cells
and p53 R246I from NCI-H23 cells) in cells treated with 250 μM CoCl2 for 4 h. IP, immunoprecipitation. (G) Coimmunoprecipitation assay of NCI-H1299 cells
treated with 800 μM CoCl2 and expressing HA-p53 R273H and different HIF-1α fragments, including the Myc-tagged N-terminal region HIF-1α, the Myc-tagged
central domain HIF-1α 401–608, and the C-terminal region HIF-1α610–826. (H) Coimmunoprecipitation assay of NCI-H1299 cells treated with 800 μM CoCl2 and
expressing Myc-HIF-1α and different fragments of HA-Flag–tagged p53 R273H DBD and HA-Flag–tagged p53 C-terminal (C-term) domain.
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Fig. 2. p53 mutants cooperate with HIF-1 in transcriptional regulation of ECM components. (A) Venn diagram of gene expression profiling analysis representing
the distribution of genes differentially regulated by p53 R273H in NCI-H1155 cells treated with normoxia or 1% oxygen (8 h). (B) Pathway clustering analysis of
301 genes differentially regulated by p53 R273H in NCI-H1155 cells treated with 1% oxygen. Pathways of major interest are highlighted in red. (C) RT-qPCR
analysis of genes encoding ECM components differentially regulated by the p53 mutants and hypoxia in NCI-H1155 cells. CTR, control. *P < 0.05, **P < 0.01,
***P < 0.001; paired two-tailed t test. Error bars indicate SD of independent biological replicates (n = 3). (D) Western blot analysis of Lam-γ2 and type VII collagen
in whole-cell extracts of NCI-H1155 cells following knockdown of p53 R273H and exposure to 1% oxygen for 24 h. MW, molecular weight (molecular mass); Nx,
normoxia. (E) ChIP-qPCR analysis of CoCl2-treated NCI-H1155 cells for the binding of HIF-1α to response elements in the proximity of the collagen VIIa1 and
collagen XIIIa1 genomic loci. (F) ChIP-qPCR analysis of CoCl2-treated NCI-H1155 cells following mutant p53 silencing by siRNA for the binding of HIF-1α to re-
sponse elements in the proximity of the collagen VIIa1 and collagen XIIIa1 genomic loci. The response element in the VEGFA and p21 genomic loci represent the
positive and negative controls, respectively, for HIF-1α binding. (G) ChIP-qPCR analysis of CoCl2-treated or untreated NCI-H1155 cells for the binding of p53
R273H to response elements in the proximity of the collagen VIIa1 genomic locus. CoCl2-treated NCI-H1155 has been subjected to 4 h with 250 μMCoCl2 and then
collected and processed, along with the untreated cells, for ChIP assay. The Mll1 transcription starting site (TSS)-proximal peak and the p21 promoter region
represent HIF-1–independent positive and negative controls for p53 mutant binding, respectively. Error bars indicate the SD of technical replicates, and the
histogram shows representative ChIP-qPCR assays of four (or more) independent biological replicates. (H) ChIP/re-ChIP analysis for the binding of p53 R273H to a
response element in the proximity of the collagen VIIa1 genomic locus performed on NCI-H1155 cells treated with 250 μM CoCl2 and subjected to two sub-
sequent immunoprecipitations (IP; as indicated in the panel). The Mll1 TSS-proximal peak represents a HIF-1–independent positive control for p53 mutant
binding. Error bars indicate the SE of three biological replicates. (I) ChIP-qPCR assay for the binding of p53 R273H to response element in the proximity of the
collagen VIIa1 genomic locus in NCI-H1155 cells following HIF-1α silencing of cells and CoCl2 treatment. NCI-H1155 cells have been transfected with siRNA control
or HIF-1α for 48 h. CoCl2-treated NCI-H1155 cells have been treated in the last 4 h of transfection with 250 μM CoCl2 and then, along with untreated cells,
collected, processed, and subjected to immunoprecipitation with p53 DO-I antibody. The Mll1 TSS-proximal pick represents a HIF-1–independent positive control
for p53 mutant binding. Error bars indicate the SE of three biological replicates. *P < 0.05, paired two-tailed t test.
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analyzed the expression level in NCI-H1155 of these ECM genes,
including type VIIa1 collagen (COL7A1), laminin-γ2 (LAMC2),
type XIIIa1 collagen (COL13A1), and laminin-γ1 (LAMC1). RT-
qPCR and Western blot analysis confirmed the ability of p53
R273H to alter the expression of these hypoxic-responsive genes
(Fig. 2 C and D and SI Appendix, Fig. S5D). In addition, mea-
surement of the levels of laminin-γ2 and type VIIa1 collagen in the
culture media from hypoxic NCI-H1155 cells indicated that mutant
p53 is necessary for hypoxia-mediated up-regulation and secretion
of these ECM components (SI Appendix, Fig. S5E). Hypoxia-
mediated up-regulation of these genes also required expression of
HIF-1 (SI Appendix, Fig. S6A). Notably, type VIIa1 collagen is a
critical player in epithelial tumorigenesis. The noncollagenous
(NC1) domain of collagen VII strictly correlates with the tumori-
genic potential of H-RASV12–transformed keratinocytes in immu-
nodeficient mice (30). The NC1 domain of collagen VII is a ligand
for laminin-332, of which laminin-γ2 is one subunit, and antibodies
inhibiting laminin-332/collagen VII interaction affect tumorigenesis
(31, 32). Thus, we decided to focus on type VIIa1 collagen and
laminin-γ2 and expanded the analysis to additional lung cancer cell
lines (NCI-H23 expressing p53 R246I and NCI-H1048 expressing
p53 R273C) to confirm p53 mutant regulation of their mRNAs (SI
Appendix, Fig. S5F). Laminin-γ2 appeared not to be expressed in
NCI-H1048 (cycle threshold higher than 35 in RT-qPCR).
We next investigated whether mutant p53 and HIF-1
colocalize in proximal regulatory regions of the genomic loci of
these genes of interest. We used the DECODE platform, which
integrates text mining applications and data from the UCSC
Genome Browser to compile lists of binding sites of human
transcription factors. We identified two potential binding sites of
HIF-1 in the proximity of the COL7A1 genomic locus (SI Ap-
pendix, Fig. S6E). Quantitative chromatin immunoprecipitation
(ChIP)-qPCR analysis confirmed the binding of HIF-1α to both
regulatory regions (Fig. 2E), and mutant p53 expression was not
required for HIF-1α binding (Fig. 2F). To verify that the p53
mutants occupy the same regulatory regions in a HIF-1–dependent
manner, we assessed the binding of mutant p53 under basal and
CoCl2 conditions. ChIP-qPCR analysis revealed a significant
increase in mutant p53 binding at both COL7A1 binding sites
upon HIF-1 activation (Fig. 2G and SI Appendix, Fig. S7A). Co-
occupancy of p53 R273H and HIF-1α at the COL7A1 genomic
locus was further confirmed by a ChIP/re-ChIP experiment
(Fig. 2H and SI Appendix, Fig. S7B), and, like the subcellular
fractionation results, HIF-1α depletion abolished mutant
p53 accumulation upon CoCl2 treatment at this site (Fig. 2I).
Two binding sites with an analogous pattern of binding were also
identified at the COL13A1 genomic locus (SI Appendix, Figs.
S6D and S7A).
HIF-1/p53 Mutant Complex Regulates Gene Expression by Influencing
SWI/SNF Chromatin Remodeling Complex. To explore the mechanism
by which mutant p53 influences the transcriptional machinery, we
tested the hypothesis that p53 R273H promotes the activity of the
chromatin remodeling complex, SWI/SNF, at HIF-1–binding sites.
Mutant p53 has been previously identified at the VEGFR2 pro-
moter region in a protein complex that included SWI/SNF (33). We
observed coimmunoprecipitation of the endogenous SWI/SNF
subunit (i.e., BAF155, Brg1) with p53 R273H in NCI-H1155 cells
(Fig. 3A and SI Appendix, Fig. S7C). Interaction between SWI/SNF
subunits and mutant p53 was also observed in normoxic conditions,
indicating the presence of a preexisting complex (Fig. 3A and SI
Appendix, Fig. S7C). Subcellular fractionation experiments showed
that SWI/SNF subunits in hypoxic NCI-H1155 cells localized to the
chromatin-bound fraction following very similar time kinetics to
HIF-1α and p53 R273H (Fig. 3B). Consistent with p53 R273H
knockdown, depletion of ATPase subunits of the SWI/SNF com-
plex, Brahma (BRM) and BRM-related gene 1 (Brg1), attenuated
hypoxic-dependent up-regulation of type VIIa1 collagen and
laminin-γ2 (Fig. 3C). Brg1 was indeed physically identified by ChIP
analysis at the genomic loci bound by the mutant p53/HIF-1 com-
plex (Fig. 3D and SI Appendix, Fig. S7D). However, SWI/SNF was
not required for the binding of p53 R273H and HIF-1α to the
genomic regions of type VIIa1 collagen and laminin-γ2 (Fig. 3 E
and F). This suggested that the SWI/SNF chromatin remodeling
complex is required for the hypoxia-mediated up-regulation of these
ECM components participating in chromatin organization, but not
in the recruitment of the mutant p53/HIF-1 transcriptional complex.
Hence, we analyzed the chromatin architecture at the type VIIa1
collagen and laminin-γ2 promoter regions, using micrococcal nu-
clease (MNase) digestion followed by qPCR. MNase digestion de-
grades DNA that is not protected from core nucleosomes
(occupancy), providing a measure of chromatin accessibility.
MNase analysis indicated that a relaxed, transcriptionally per-
missible, open chromatin was produced by 24 h of hypoxia at the
type VIIa1 collagen, laminin-γ2, and VEGFA genomic regions,
although expression of mut-p53 was required to support the
hypoxia-induced remodeling of the chromatin architecture at the
type VIIa1 collagen and laminin-γ2 sites, but not on the promoter
of VEGFA (Fig. 3G), whose expression is not influenced by
mutant p53 (SI Appendix, Fig. S4A). H3K4me and H3K27Ac at
the COL7A1 and COL13A1 genomic regions indicated that, in
NCI-H1155 cells, ColVII (−)10A and (+)09A areas represent
active transcriptional enhancers (SI Appendix, Figs. S7 E and F
and S8 A–D). Consistent with the result of the MNase assay,
depletion of p53 R273H abolished the hypoxia-induced nucleo-
somal displacement at the COL7A1 genomic site as assessed by
histone H2A.Z content (Fig. 3H). Overall, these data indicate
that mutant p53 promotes expression of HIF-1–dependent ECM
components by facilitating chromatin remodeling mediated by
SWI/SNF.
HIF-1/p53 Mutant/ECM Axis Induces Aggressive Phenotype of NSCLC
Cells. We next addressed the importance of this ECM signaling to
the tumor-relevant phenotype of NSCLC. Exposure for 24 h to 1%
O2 significantly increased cellular migration and invasion, and de-
pletion of the p53 mutants substantially reversed this effect (Fig. 4 A
and B and SI Appendix, Fig. S9 A–D). The importance of type
VIIa1 collagen and laminin-γ2 as downstream effectors of p53
mutant/HIF-1 protumorigenic signaling was confirmed by their ca-
pacity to revert the loss of migration and invasion potential in mu-
tant p53-deficient hypoxic cells (Fig. 4 A and B). The specificity of
type VIIa1 collagen and laminin-γ2 in the p53 mutant/HIF-1 axis
was further proven by the inability of an unrelated ECM component,
laminin-α5, to revert the phenotype associated with mutant
p53 depletion (Fig. 4 A and B). In addition, consistent with a
paracrine role exerted by ECM components, invasion of untrans-
fected cells was altered by conditioned media derived from hypoxic
cells proficient or deficient for p53 mutants (Fig. 4C). In agreement
with a protumorigenic role of the laminin-322/collagen VII in-
teraction (31, 32), they produced hyperactivation of AKT signaling
(pAKT T308) (Fig. 4D). Hence, we also asked whether this axis could
enhance cell growth potential in vitro and in vivo. Overexpression of
laminin-γ2 or type VIIa1 collagen increased only marginally the in
vitro proliferation rate of NCI-H1155 cells (Fig. 4E). However, we
reasoned that the biological effect of the laminin-332/collagen VII-
driven ECM remodeling should be assessed by recapitulating the
interaction of the cancer cells, stroma, and ECM in a real tumor
microenvironment. To this end, we tested whether our axis could
enhance tumor growth in mouse cancer models generated by
xenotransplantation of human cancer cell lines. We inocu-
lated NCI-H1155 cells stably overexpressing laminin-γ2 or type
VIIa1 collagen into immunocompromised mice. Expression of
both ECM components promoted tumor growth, but type VIIa1
collagen-overexpressing cells displayed a substantial enhancement of
tumor growth (Fig. 5 A–C and SI Appendix, Fig. S9 E and F).
Consistently, when we deleted p53 R273H in NCI-H1155 by a
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Fig. 3. HIF-1/mutant p53 directly controls transcription of ECM components involving the SWI/SNF chromatin remodeling complex. (A) Coimmunoprecipi-
tation assay performed by immunoprecipitating mutant p53 in untreated or CoCl2-treated (for 4 h with 250 μM) NCI-H1155 cells and immunoblotting for p53,
the SWI/SNF subunits (BAF155 and Brg1), HIF-1α, and the control GAPDH (4 h at 1% O2). IP, immunoprecipitation; MW, molecular weight (molecular mass);
Unt, untreated. (B) Western blot analysis of subcellular fractions (nuclear-soluble and chromatin-bound fractions) of NCI-H1155 treated with a time course
(0–24 h) of 1% oxygen. Chr, chromatin-bound fraction; Nucl, soluble nuclear fraction. (C) RT-qPCR analysis of genes encoding ECM components following
silencing of SWI/SNF ATPase subunit BRM and Brg1 in hypoxic NCI-H1155 cells (24 h at 1% O2). CTR, control. *P < 0.05, **P < 0.01; paired two-tailed t test.
Error bars indicate the SE of independent biological replicates (n = 3). (D) ChIP-qPCR assay for the binding of the SWI/SNF ATPase subunit Brg1 in NCI-
H1155 cells treated for 4 h with 250 μM CoCl2. VEGFR2 (−150 bp) and VEGFR2 (+30 Kb) represent positive and negative controls, respectively, of Brg1 binding.
Error bars indicate the SE of technical replicates, and the histogram shows representative ChIP-qPCR assays of three independent biological replicates. (E)
ChIP-qPCR analysis of CoCl2-treated NCI-H1155 cells following concurrent Brg1 and BRM silencing by siRNA for the binding of mutant p53 to response el-
ements in the proximity of the collagen VIIa1 and collagen XIIIa1 genomic loci. Error bars indicate the SE of independent biological replicates (n = 3). (F) ChIP-
qPCR analysis of CoCl2-treated NCI-H1155 cells following concurrent Brg1 and BRM silencing by siRNA for the binding of HIF-1α to response elements in the
proximity of the collagen VIIa1 and collagen XIIIa1 genomic loci. Error bars indicate the SE of independent biological replicates (n = 3). (G) Chromatin was
digested with MNase, and mononucleosome-sized DNA fragments were isolated. qPCR was performed on the promoter regions of the hypoxic-responsive
genes Lam-γ2, type VII collagen, and VEGFA. Error bars represent the SE of three independent experiments. *P < 0.05, paired two-tailed t test. (H) ChIP-qPCR
assay assessing the content of histone H2A.Z at the collagen VIIa1 genomic locus in p53-depleted NCI-H1155 cells following 16 h of hypoxia (at 1% O2). Error
bars indicate the SE of technical replicates, and the histogram shows representative ChIP-qPCR assays of three independent biological replicates.
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doxycycline-responsive inducible CRISPR/Cas9 system (SI Appendix,
Fig. S9G), tumor growth of hypoxic preconditioned cells was dra-
matically reduced, and this was significantly reverted by reexpression
of laminin-γ2 or type VIIa1 collagen (Fig. 5 D–F and SI Appendix,
Fig. S9H). Together, our data demonstrate the ability of p53 mu-
tants to promote a tumor-relevant phenotype through modu-
lation of ECM components by a GOF effect on HIF-1.
ECM Signature Correlates with Hypoxia and p53 Mutants in Human
NSCLC with Poor Prognosis. Next, we validated whether the syner-
gistic effect of mutant p53 and HIF-1 on the regulation of ECM
components was present in human NSCLC. First, we assessed
whether mutant p53 and HIF-1 influenced the expression levels of
the ECM genes of interest in patients with NSCLC. We extracted
RNA from 45 surgically resected tumor tissues and performed
RT-qPCR analysis to evaluate HIF-1 activation, assessed by the
expression level of 10 well-established HIF-1 targets (hypoxia
signature) and our genes of interest. Next, we calculated the
Pearson correlation coefficients between the expression of our
genes of interest and the hypoxia signature. We stratified the
samples according to the p53 mutational status, and we observed
that the Pearson correlation coefficient between the hypoxia
signature and type VIIa1 collagen or laminin-γ2 expression was
significant exclusively in the samples expressing mutant p53 (R =
0.58 for COL7A1 and R = 0.70 for Lam-γ2) (Fig. 6 A and B).
We also analyzed the expression level of our genes of interest in
“low-hypoxia” and “high-hypoxia” tumors following stratification
for p53 mutational status. Here, expression levels of type VIIa1
collagen and laminin-γ2 were selectively increased in high-hypoxia
tumors expressing a mutant form of p53 (SI Appendix, Fig. S10 A
and B). To confirm these data at the protein level, we employed a
human adenocarcinoma tissue microarray, including 275 cores of
110 clinical cases. More than 60% of the cases showed moderate to
high expression of laminin-γ2 (Fig. 6C and SI Appendix, Fig. S10C).
Analysis of the expression of a hypoxic marker, such as carbonic
anhydrase IX (CAIX), and laminin-γ2 also confirmed that the
correlation between hypoxia and our ECM signature is present
exclusively in tumors expressing mutant p53 (Fig. 6 C and D and SI
Appendix, Fig. S10D). Both CAIX and laminin-γ2 were associated
with histological invasion patterns predominantly in mutant
p53 cores (Fig. 6 C and D), thus confirming the existence of a
synergism between hypoxic signaling and p53 mutations. We next
analyzed larger cohorts of patients to further validate the clinical
data. To this end, we developed p53MutaGene, a computational
tool designed to assess the effect of the p53 status on gene regu-
lation (34). The algorithm stratified a cohort of ∼300 patients with
NSCLC according to p53 mutational status and computed the
correlation between the expression of our genes of interest and the
activation of HIF-1 (measured as the expression of direct HIF-
1 target genes). Strikingly, p53MutaGene reported statistically sig-
nificant differential coexpression of HIF-1 targets and our genes of
interest between samples expressing wt p53 and those expressing
mutant p53 (Fig. 6 E and F and SI Appendix, Fig. S11 A and B).
Mutant p53 expression was always associated with a higher positive
Pearson correlation coefficient. Analysis of the Molecular Taxon-
omy of Breast Cancer International Consortium (METABRIC)
human cancer dataset also revealed a very similar trend in breast
cancer (SI Appendix, Fig. S11 C–E). Our analyses confirm that
p53 mutants can potentiate the ability of HIF-1 to drive the ex-
pression of ECM components in a clinical setting. In support of this,
we also identified a tendency for mutual exclusivity between mutant
p53 and laminin-γ2 genomic locus amplification in human NSCLC
datasets (SI Appendix, Fig. S12C).
Finally, to validate the impact of this signaling pathway on
cancer progression, we evaluated the clinical outcomes of patients
highly expressing genes belonging to the mutant p53/HIF-1 sig-
nature. Survival analysis of NSCLC datasets (35), computed by
grouping our samples into cohorts expressing high levels of type
VIIa1 collagen and laminin-γ2, revealed that patients with ele-
vated expression of this gene signature had a shorter lifespan (Fig.
6G and SI Appendix, Fig. S12 A and B). Consistently, high levels of
type VIIa1 collagen and laminin-γ2 were significantly associated
with more aggressive NSCLC (SI Appendix, Fig. S12D).
These data, based on analysis of clinical material from patients
who had cancer, demonstrate the existence in a human disease
setting of a molecular axis involving HIF-1/mutant p53/ECM and
indicate that this signaling is preferentially associated with the
most aggressive tumors.
Discussion
Our data reveal a GOF mechanism of p53 mutants on the
transcriptional activity of HIF-1 in hypoxic NSCLC cells. The
interplay between the wt members of the p53 family and HIFs
has long been a subject of intense study, and reciprocal regula-
tion between these two families of genes has been shown (15, 22,
36). Mutations in the TP53 gene and activation of HIF-1 in
Fig. 4. Type VIIa1 collagen and laminin-γ2 promote
a p53 mutant/HIF-1–dependent proinvasive pheno-
type. (A and B) p53 mutants affect hypoxia-mediated
migration and invasion of NCI-H1155 and NCI-H23
NSCLC cells, and overexpression of type VIIa1 colla-
gen and laminin-γ2 reverts this impairment. CTR,
control; pCMV6, empty vector-transfected control
cells. *P < 0.05, **P < 0.02; two-tailed paired t test.
Error bars indicate the SE of independent biological
replicates (n = 5 for NCI-H1155, n = 3 for NCI-H23). (C)
Conditioned media (CM) from corresponding p53
mutant silenced cells treated for 24 h with 1% oxygen
alter the migration and invasion capacity of NCI-
H1155 and NCI-H23 NSCLC cells. *P < 0.05, **P <
0.01; two-tailed paired t test. Error bars indicate the
SE of independent biological replicates (n = 4 for NCI-
H1155, n = 3 for NCI-H23). (D) Western blot analysis of
NCI-H1155 cells stably overexpressing type VIIa1 col-
lagen or laminin-γ2 displays hyperactivation of pAKT
T308. EV, empty vector; MW, molecular weight (mo-
lecular mass). (E) Proliferation doublings of NCI-
H1155 cells stably overexpressing type VIIa1 collagen
or laminin-γ2. *P < 0.05, **P < 0.01; paired two-tailed
t test. Error bars indicate the SE of independent bi-
ological replicates (n = 4).
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hypoxic areas are frequently observed in advanced cancer, in-
cluding NSCLC. Our data indicate that co-occurrence of these
two events is associated with a significantly worse prognosis
(Fig. 1A). The results of our study shed light on the molecular
determinants underlining the aggressive phenotype of these tu-
mors. Here, we identify a direct interplay between mutant forms
of p53 and HIF-1 in NSCLC cells.
We observed a physical interaction between p53 mutants and
the regulatory subunit of HIF-1, HIF-1α. The result of this in-
teraction is the formation of a transcriptional complex that
regulates expression of downstream targets, such as the ECM
components type VIIa1 collagen and laminin-γ2. In particular,
while HIF-1α recruits and shuttles mutant p53 to the DNA ge-
nomic elements, mutant p53 does not influence HIF-1 binding to
the DNA but impinges on its transcriptional activity. The binding
of mutant p53 to the genomic elements is, however, not com-
pletely abolished by HIF-1α depletion, indicating that other
factors also participate in this process. The cooperation of p53
mutants and HIF-1 in the transcriptional regulation of ECM
genes involves chromatin remodeling mediated by the SWI/SNF
complex, in keeping with a recent study by Prives and coworkers
(33) that implicated SWI/SNF activity in the p53 mutant-
dependent transcriptional regulation of VEGF-R2 in breast
cancer cells. Mechanistically, the SWI/SNF complex does not
influence the binding of mutant p53/HIF-1 to the genomic sites
of the ECM genes. However, its ATPase subunits Brg1 and
BRM are required for the hypoxia-induced up-regulation of type
VIIa1 collagen and laminin-γ2, probably by mediating the mutant
p53-dependent changes in the chromatin architecture. The impact
of p53 mutants on the cancer cell epigenome and chromatin or-
ganization therefore appears to be a potential key mechanistic
aspect for p53 mutants oncogenic properties and consequentially
also an important therapeutic avenue to explore.
Type VIIa1 collagen and laminin-γ2 critically contribute to the
HIF-1/mutant p53-dependent tumor phenotype. Our in vivo and
in vitro studies demonstrated that reexpression of laminin-γ2 and
type VIIa1 collagen in NSCLC cells reverts the tumorigenic
properties lost upon depletion of the endogenous mutant p53.
Importantly, correlation of the expression of these ECM genes
with HIF-1 activation is observed only in human NSCLC carrying
p53 mutations, and this observation was consistently reproduced
in different settings: mRNA of a cohort of 45 surgically resected
NSCLCs; tissue microarray of ∼100 NSCLCs; and large, publicly
available gene expression profile datasets of lung cancers. Re-
markably, laminin-γ2 in hypoxic p53 mutant human NSCLC is
associated with an invasive histological pattern that represents a
hallmark of advanced tumor areas.
A major implication of our findings is indeed the flexibility of
p53 mutants in acquiring selective GOF properties under specific
cellular stress conditions. Our data clearly imply that in hypoxic
tumors, p53 mutants can acquire protumorigenic properties not
observed under other conditions. This flexibility can be expanded
also to intratumoral heterogeneity and plasticity, which can give
rise to specific tumor areas where the synergistic activity of
Fig. 5. Type VIIa1 collagen and laminin-γ2 promote the p53 mutant/HIF-1–dependent protumorigenic phenotype in vivo. (A and B) NCI-H1155 cells stably over-
expressing type VIIa1 collagen or laminin-γ2 injected s.c. into immunocompromised mice grow faster than empty vector-transfected cells. (A) Columns indicate distribution
of tumor weight. Gray lines indicate the average of the distribution. P values are indicated in the corresponding panel (unpaired two-tailed t test; n = 4 for
NCI-H1155 cells, NCI-H1155 CollVIIa1 and Lam-γ2). CTR, control. (B) Photographs of tumors after dissection. Full photography of tumors after dissection is
shown in SI Appendix, Fig. S9E. (C) Composite images of mice and fluorescent tumor signals (mCherry) were acquired a day before the end point using an
IVIS Spectrum In Vivo Imaging System (PerkinElmer). (D–F) Genetic deletion of p53 R273H by inducible CRISPR/Cas9 in NCI-H1155 cells significantly impairs
tumor growth after s.c. transplantation in immunocompromised mice, and overexpression of type VIIa1 collagen or laminin-γ2 reverts this effect.
NCI-H1155 Tet-On guide RNA (gRNA) p53 cells (parental, type VIIa1 collagen-overexpressing, or laminin-γ2–overexpressing) were treated for 72 h with 2 μg/mL
doxycycline and exposed for the last 24 h before injection with 1% oxygen. (D) Columns indicate distribution of tumor weight. Gray lines indicate
average of the distribution. P values are indicated in the corresponding panel (two-tailed unpaired t test; n = 4 for p53 R273H+/+ and p53 R273H−/−
laminin-γ2 groups, n = 5 for p53 R273H−/− and p53 R273H−/− type VII collagen groups). (E ) Representative hematoxylin/eosin images of xenograft tumors
from F. (Scale bars: Left, 2 mm; Right, 500 μm.) (F ) Photographs of tumors after dissection. Full photography of tumors after dissection is shown in SI
Appendix, Fig. S9H.
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hypoxic-driven HIF-1 and p53 mutations produces tissue niches
with a high degree of aggressiveness that favors evolution of the
tumor to a lethal phenotype.
Our results shed light on the molecular determinants potentially
implicated in advanced stages of tumorigenesis. In addition, these
findings highlight potential novel therapeutic interventions aimed
Fig. 6. p53 mutants and HIF-1 synergistically act in human NSCLC. (A and B) Correlation analysis of mRNA expression levels in surgically resected human NSCLC
specimens based on RT-qPCR in blue samples expressing wt p53 and in red samples expressing mutant p53. P values are indicated in the corresponding panel (wt
p53, n = 22; p53mutant, n = 23). R, Pearson correlation coefficient; RQ, relative quantification. (C, Left) Representative images of the immunohistochemical staining
for CAIX and Lam-γ2 on the human lung adenocarcinoma tissue microarray. (C, Right) Pie chart reports the median distribution of Lam-γ2 staining in the 110 cases
analyzed. (Scale bar: 100 μm.) (D) Correlation between expression of CAIX and Lam-γ2 (Upper) and the correlation between histological invasion and CAIX or Lam-
γ2 (Lower) are shown. Correlation coefficients have been calculated as Spearman’s rho. P values are indicated in the corresponding panel. Computation has been
performed on tumor cores (All, n = 210; p53 wt, n = 111; p53 mut, n = 99). pos, positive. (E and F) Correlations between the expression of HIF-1 targets and our
genes of interest, Col VIIa1 and Lam-γ2, were computed in two cohorts of a human NSCLC dataset (GSE36471) stratified according to p53 status (n = 292; Pearson
correlation coefficients and P values are indicated in the corresponding panel). ALDOA, Aldolase A. (G) Kaplan–Meier plots indicating the overall survival estimates
for patients with NSCLC expressing high levels of Col VIIa1 and Lam-γ2. P values are indicated in the corresponding panel. TCGA, The Cancer Genome Atlas.
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at targeting the mutant p53/HIF-1 interaction to minimize the
dissemination of human NSCLC.
Materials and Methods
Xenotransplanted Tumor Model. BALB/c nude l (nu/nu) mice were purchased
from Charles River Laboratories and then housed in the central research
facility of the University of Leicester. All experimental work involving animals
was approved by the local ethical committee and performed in accordance
with United Kingdom legislation. The experiment was performed on sex-
matched, age-matched, and strain-matched mice. All of the experiments
have been performed by s.c. injection into 6- to 8-wk-old nu/nu mouse 1 ×
106 NCI-H1155 cells resuspended in DMEM/F12 (1:1) medium (Invitrogen).
Two weeks after injection, tumors were collected, weighed using an Ana-
lytical Balance Scale (Fischer Brand), fixed in 4% paraformaldehyde (48 h),
and embedded in paraffin. For the experiment with prior injection of tet-
racycline (Tet)-On–inducible NCI-H1155 cells, cells were treated for 72 h
with doxycycline (2 μg/mL) and 24 h of 1% oxygen exposure. Hematoxylin/
eosin staining was performed as previously described (37) on paraffin-
embedded sections. In brief, after deparaffinization and rehydration, the
sections were stained for 5 min with hematoxylin, and then washed in
distilled water for 3 min and incubated for 1 min in 1% HCl/70% alcohol.
The sections were then washed in distilled water and stained for 1 min in
1% eosin. The images were captured with a Hamamatsu NanoZoomer XR
digital pathology slide scanner, and images were processed with NDP.
view.2.3.1 software (Hamamatsu).
Generation of Tet-On–Inducible NCI-H1155 CRISPR/Cas9 Cells. For generation of
an inducible CRISPR/Ca9 system, we employed the previously described sys-
tem based on FUCas9Cherry and FgH1UTG plasmids (38). NCI-H1155 cells
were infected with lentiviral vectors carrying expression of constitutive
Cas9 (FUCas9Cherry) and doxycycline-inducible guide RNA (FgH1UTG). To
produce lentiviral particles, 293T cells were transiently transfected with
vector DNA, along with the packaging constructs pMDLg/pRRE (catalog no.
12251; Addgene), pRSV-rev (catalog no. 12253; Addgene), and pMD2.G
(catalog no. 12259; Addgene), and the target plasmid using Effectene
transfection reagent (catalog no. 301425; Qiagen) according to the guide-
lines provided. Virus-containing supernatants were collected at 48 h after
transfection and filtered with a 0.45-μm filter. NCI-H1155 cells were infected
with a suspension of virus-containing supernatant with 8 μg/mL polybrene
and incubated for 24 h at 37 °C. Virally transduced cell lines were then sorted
using a FACSAriaII (Becton Dickinson) flow cytometer. All cells positive for
mCherry (FUCas9Cherry) and EGFP (FgH1UTG) were sorted to produce a
whole population of double-positive cells. To induce single-guide RNA
(sgRNA) expression, virally transduced and sorted cells were treated for 72 h
with 2 μg/mL doxycycline hyclate (D9891; Sigma). The Massachusetts In-
stitute of Technology CRISPR design software was used for the design of
sgRNAs (crispr.mit.edu). Detailed material and methods are provided in SI
Appendix, Supplementary Materials and Methods.
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